close

Agreements

1 2 3 4 5 228
Number of results: 4541

Excel print is not allowed for data more than 3000.Please search above for fewer data.

Date Company Compound Disease Type of agreement Therapeutic area Type of Information
2017-12-20 Bluebird bio (USA - MA) Merck KGaA (Germany) viral vectors manufacturing - production Production agreement
2017-12-20 TiGenix (Belgium) Autoimmune diseases - Inflammatory diseases - Digestive diseases Restructuring
2017-12-20 BMS (USA - NY) Taris Biomedical (USA - MA) Opdivo® (nivolumab) and TAR-200 (GemRIS™) muscle invasive bladder cancer (MIBC) clinical research Cancer - Oncology Clinical research agreement
2017-12-19 Theradiag (France) HOB Biotech Group (China) LISA TRACKER® monitoring assays, auto-immunity IVD tests co-development - distribution Diagnostic - Autoimmune diseases - Immunological diseases Distribution agreement
2017-12-19 Confo Therapeutics (Belgium) Roche (Switzerland) small molecule agonists of an undisclosed G-protein coupled receptor (GPCR) research - licensing - commercialisation Neurological diseases - Developmental diseases Research agreement
2017-12-19 Boehringer Ingelheim (Germany) Roche (Switzerland) Locked Nucleic Acid (LNA) oligonucleotides inflammatory bowel diseases research - R&D - development Autoimmune diseases - Inflammatory diseases - Digestive diseases Research agreement
2017-12-19 Celltrion Healthcare (South Korea) Hikma Pharmaceuticals (UK) Truxima® (CT-P10 - biosimilar rituximab - biosimilar version of Mabthera®/Rituxan® ) non-Hodgkin's lymphoma, chronic lymphocytic leukemia, rheumatoid arthritis, granulomatosis with polyangiitis, microscopic polyangiitis licensing Autoimmune diseases – Inflammatory diseases - Rheumatic diseases - Cancer - Oncology Licensing agreement
2017-12-18 Ultragenyx Pharmaceutical (USA - CA) Novartis (Switzerland) Rare Pediatric Disease Priority Review Voucher (PPRV) commercialisation Rare diseases - Genetic diseases Commercialisation agreement
2017-12-18 Autifony Therapeutics (UK) Boehringer Ingelheim (Germany)
  • Kv3.1/3.2 positive modulator platform including AUT00206
schizophrenia, hearing disorders, orphan CNS disorders including fragile X syndrome CNS diseases - Otorhinolaryngology - Psychiatric diseases - Rare diseases Research agreement
2017-12-18 Sensorion (France) Cochlear Limited (Australia) SENS-401 (R-azasetron besylate) in combination with cochlear implants collaboration - licensing Otorhinolaryngology Collaboration agreement
2017-12-18 Oxford Genetics (UK) MeiraGTx (USA - NY) novel adeno-associated virus (AAV) vectors, packaging and producer cell lines development - manufacturing - production Rare diseases - Genetic diseases - Technology - Services Development agreement
2017-12-15 Genethon (France) Orchard Therapeutics (UK) Yposkesi (France)
  • G1XCGD lentiviral vector (autologous haematopoietic cells genetically modified with a lentiviral vector containing the human gp91(phox) gene)
 
X-linked chronic granulomatous disease (X-CGD) research - development - licensing Rare diseases - Genetic diseases Licensing agreement
2017-12-15 Mesoblast (Australia) Tigenix (Belgium) Cx601 (adipose derived allogeneic stem cell therapy) licensing Licensing agreement
2017-12-14 Teva Pharmaceutical (Israel) restructuring Restructuring
2017-12-14 Samsung Medical Center (Republic of Korea) A*STAR’s Genome Institute of Singapore (GIS) (Singapore) Institute of Molecular and Cell Biology (IMCB) (Singapore) National Cancer Centre Singapore (NCCS) (Singapore) National University of Singapore (NUS) (Singapore) hepatocellular carcinoma collaboration - research Cancer - Oncology Collaboration agreement
2017-12-13 Evotec (Germany) Center for Regenerative Therapies TU Dresden (CRTD) (Germany) small molecule candidates for retinal diseases retinal diseases research Ophtalmological diseases Research agreement
2017-12-12 CRISPR Therapeutics (Switzerland - UK) Vertex Pharmaceuticals (USA - MA) CRISPR’s gene editing technology, known as CRISPR-Cas9, CTX001 cystic fibrosis, hemoglobinopathies, including sickle cell disease R&D - research - development Rare diseases - Genetic diseases - Hematological diseases R&D agreement
2017-12-12 Chugai Pharmaceutical (Japan) chief executive officer nomination Cancer - Oncology - Immunological diseases Nomination
2017-12-12 Allergy Therapeutics (UK) Ergomed (UK) three OralVac immunotherapy products grass pollen allergy, tree pollen allergy, house dust mite allergy development Allergic diseases - Immunological diseases - Respiratory diseases Development agreement
2017-12-12 Eyevensys (France) chief executive officer nomination Rare diseases - Genetic diseases - Ophtalmological diseases Nomination